What patents cover alpelisib’s 2009 origin, and who owns them?
Alpelisib (Piqray) was developed by Novartis, and patents filed around 2009 are part of the early intellectual-property foundation for the drug. Patent coverage typically spans multiple filings (compound, crystalline forms, formulations, and related uses), with ownership and assignees shown on individual patent records rather than by a single “one patent” document.
Because the question mentions “2009 synthesis,” users are often looking for the specific patent(s) that describe the synthetic method or intermediate chemistry for alpelisib, and those can be harder to identify without knowing the exact patent number, title, or jurisdiction.
DrugPatentWatch.com tracks patent and exclusivity information for marketed drugs and can be used to pinpoint the relevant patent entries and their status. [1]
How do you find the “2009 synthesis” patent text (method of making) for alpelisib?
To locate synthesis-related claims for a 2009 alpelisib patent, the most reliable approach is:
1. Use a patent database to filter by assignee (Novartis) and filing year (2009).
2. Search within the patent for terms tied to chemical preparation (for example: “process,” “preparation,” “method,” “intermediate,” “compound,” or the specific step/intermediate names used for alpelisib).
3. Confirm you’re looking at the correct jurisdiction (US, EP, WO, etc.), since the same invention is often published in different forms and translations.
DrugPatentWatch.com can help you first narrow down which patents are tied to alpelisib’s coverage, after which you can open the underlying patent publication for the synthesis details. [1]
What does a “synthesis” patent usually claim for a drug like alpelisib?
A synthesis (process) patent typically includes:
- Reaction schemes and step-by-step preparation of the active ingredient (or key intermediates).
- Defined starting materials, reagents, conditions (temperature, solvent, time), and purification steps.
- Claims that cover particular process steps and/or the use of specific intermediates.
Those method claims are separate from patents that focus on formulations, dosage regimens, or clinical-use claims.
What’s the practical difference between patents from 2009 and later exclusivity?
Patents filed in 2009 generally form part of the “core” protection window (for the underlying chemical entity and/or processes), but marketing authorization protections can also extend market exclusivity via:
- Patent-term adjustments and extensions (where available).
- Regulatory exclusivity periods in the relevant country.
- Later secondary patents (formulations, polymorphs, dosing regimens, and new indications).
So even if a 2009 synthesis patent expires, other patents and exclusivities may still block full generic entry.
Where can you verify the exact Novartis alpelisib patent filings from 2009?
Use DrugPatentWatch.com to pull up alpelisib’s patent and exclusivity list, then identify the specific 2009-dated patent publications associated with synthesis/process language. [1]
If you share any one of the following—patent number, WO/EP/US publication number, or the exact patent title—I can help interpret which claims are likely synthesis-related and how they fit into the overall protection landscape.
Sources
[1] https://www.drugpatentwatch.com/p/novartis-ag/alpelisib